Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Eric Weisblum, CEO of Silo Pharma…


Previous articleEyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and Joe Moore
Next articleAlgernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study